糖皮质激素治疗肝衰竭研究现状

王秀芳; 冯国和

doi:10.3969/j.issn.1001-5256.2018.07.043

糖皮质激素治疗肝衰竭研究现状

DOI: 10.3969/j.issn.1001-5256.2018.07.043

中国医科大学附属盛京医院感染科

详细信息

中图分类号: R575.3
计量
- 文章访问数: 1840
- HTML全文浏览量: 35
- PDF下载量: 434
- 被引次数: 0
出版历程
- 收稿日期: 2017-12-26
- 出版日期: 2018-07-20

Research advances in glucocorticoids for the treatment of liver failure

Department of Infectious Diseases, Shengjing Hospital of China Medical University

摘要

摘要: 糖皮质激素(GCs)由于其抗炎和免疫抑制作用而广泛应用于伴有炎症状态的肝病治疗中,尤其应用于自身免疫性肝炎及淤胆型肝炎。但是国内外学者对于GCs是否应用于肝衰竭的治疗尚存在争议。一方面,有学者认为GCs可抑制免疫,导致免疫功能紊乱,诱发细菌及真菌感染,进而增加病死率;另一方面,也有学者认为其可抑制免疫应答、减轻炎症反应、减少肝细胞坏死,发挥保护肝细胞、延长生存周期的作用。综述了GCs治疗肝衰竭的机制,应用时机、剂量,不同病因肝衰竭中GCs的应用以及应用期间的观察指标等研究现状。
- 糖皮质激素类 /
- 肝功能衰竭 /
- 治疗 /
- 综述
Abstract: Glucocorticoids ( GCs) are widely used in the treatment of liver diseases accompanied by inflammation due to its strong anti-inflammatory and immunosuppressive effects, especially autoimmune hepatitis and cholestatic hepatitis. However, there are still controversies over the use of GCs in the treatment of liver failure among Chinese and foreign scholars. On the one hand, some scholars think that GCs can suppress immune function, cause immune dysfunction, induce bacterial and fungal infections, and thus increase mortality; on the other hand, some scholars believe that GCs can suppress immune response, reduce inflammatory response and hepatocyte necrosis, and thus protect hepatocytes and prolong survival. This article reviews the mechanism, opportune administration, and dosage of GCs in the treatment of liver failure, as well as the current status of the research on the application of GCs in liver failure of different etiologies and observation indices during application.
- glucocorticoids /
- liver failure /
- therapy /
- review

HTML全文

参考文献(43)

[1]DEJAGER L, PETTA I, BALLEGEER M, et al.The Interactome of the glucocorticoid receptor and its influence on the actions of glucocorticoids in combatting inflammatory and infectious diseases[J].Mol Biol Rev, 2016, 80 (2) :495-522.

[2]KHARB S, GARG MK, PURI P, et al.Assessment of adrenal function in liver diseases[J].Indian J Endocrinol Metab, 2013, 17 (3) :465-471.

[3]KRENKEL O, MOSSANEN JC, TACKE F.Immune mechanisms in acetamin-ophen-induced acute liver failure[J].Hepatobiliary Surg Nulr, 2014, 3 (6) :331043.

[4]NICOLAIDES NC, KYRATZI E, LAMPROKOSTOPOULOU A, et al.Stress, the stress system and the role of glucocorticoids[J].Neuroimmunomodulation, 2015, 22 (1-2) :6-19.

[5]MIYATA M, LEE JY, SUSUKI-MIYATA S, et al.Glucocorticoids supperess inflammation via the upregulationof negative regulator IRAK-M[J].Nat Commun, 2015, 6:6062.

[6]KIM EJ, LEE JG, KIM JY, et al.Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets[J].Immunology, 2017, 152 (4) :628-637.

[7]DEJAGER L, VANDEVYVER S, PETTA I, et al.Dominance of the strongest:Inflammatory cytokines Versus glucoconicoids[J].Cytokine Growth Factor Rev, 2014, 25 (1) :21-33.

[8]OAKLEY RH, CIDLOWSKI JA.The biology of the glucoconicoid receptor:New signaling mechanisms in health and disease[J].J Allergy Clin Immunol, 2013, 132 (5) :1033-1044.

[9]LINOSSI EM, BABON JJ, HILTON DJ, et al.Suppression of cytokine signaling:The SOCS perspective[J].Cytokine Growth Factor Rev, 2013, 24 (3) :241-248.

[10]PHILIP AM, VIJAYAN MM.Stress-immune-growth interactions:Cortisol modulates suppressors of cytokine signaling and JAK/STAT pathway in rainbow trout liver[J].PLo S One, 2015, 10 (6) :e0129299.

[11]KWON HJ, WON YS, PARK O, et al.Opposing effects of prednisolone treatment on T/NKT cell-and hepatotoxin-mediated hepatitis in mice[J].Hepatology, 2014, 59 (3) :1094-1106.

[12]CHEN JF, WANG KW, ZHANG SQ, et al.Dexamethasone in outcome of patients with hepatitis B virus-related acute-on-chronic liver failure[J].J Gastroenterol Hepatol, 2014, 29 (4) :800-806.

[13]ZHANG XQ, JIANG L, YOU JP, et al.Efficacy of short term dexamethasone therapy in acute-on-chronic pre-liver failure[J].Hepatol Res, 2011, 41 (1) :46-53.

[14] THURSZ MR, RICHARDSON P, ALLISON M, et al.Prednisolone or pentoxifylline for alcoholic hepatitis[J].N Engl J Med, 2015, 372 (17) :1619-1628.

[15]MENDIZABAL M, MARCIANO S, VIDELA MG, et al.Fulminant presentation of autoimmune hepatitis:Clinical features and early predictors of corticosteroid treatment failure[J].Eur J Gastroenterol Hepatol, 2015, 27 (6) :644-648.

[16]ZHAO B, ZHANG HY, XIE GJ, et al.Evaluation of the efficacy of steroid therapy on acute liver failure[J].Exp Ther Med, 2016, 12 (5) :3121-3129.

[17]SHASTHRY SM, SARIN SK.New treatment options for alcoholic hepatitis[J]World J Gastroenterol, 2016, 22 (15) :3892-3906.

[18] ZHU B, YOU SL, WAN ZH, et al.Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure[J].World J Gastroenterol, 2014, 20 (23) :7473-7479.

[19]BOCKMANN JH, DANDRI M, LUTH S, et al.Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure[J].World J Gastroenterol, 2015, 21 (7) :2214-2219.

[20]FUJIWARA K, YASUI S, YONEMITSU Y, et al.Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure[J].Hepatol Res, 2014, 44 (5) :491-501.

[21]D'AGNOLO HM, DRENTH JP.High-dose methylprednisolone-induced hepatitis in a patient with multiple sclerosis:A case report and brief review of literature[J].Neth J Med, 2013, 71 (4) :199-202.

[22]OLIVEIRA AT, LOPES S, CIPRIANO MA, et al.Induced liver injury after high-dose methylprednisolone in a patient with multiple sclerosis[J].BMJ Case Rep, 2015, 2015:bcr2015210722.

[23]XUAN D, YU Y, SHAO L, et al.Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy—a report of long-term follow-up of serial cases and literature review[J].Clin Rheumatol, 2014, 33 (4) :577-586.

[24]HE B, ZHANG Y, LV MH, et al.Glucocorticoids can increase the survival rate of patients with severe viral hepatitis B:A meta-analysis[J].Eur J Gastroenterol Hepatol, 2013, 25 (8) :926-934.

[25]KOSKINAS JS, DEUTSCH M, ADAMIDI S, et al.The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients.A real life experience from a tertiary center[J].Eur J Intern Med, 2014, 25 (8) :768-771.

[26]YASUI S, FUJIWARA K, NAKAMURA M, et al.Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B[J].J Viral Hepat, 2015, 22 (2) :92-100.

[27]PARKER R, ARMSTRONG MJ, CORBETT C, et al.Systematic review:pentoxifylline for the treatment of severe alcoholic hepatitis[J].Aliment Pharmacol Ther, 2013, 37 (9) :845-854.

[28] THURSZ MR, RICHARDSON P, ALLISON M, et al.Prednisolone or pentoxifylline for alcoholic hepatitis[J].N Engl J Med, 2015, 372 (17) :1619-1628.

[29]FACCIORUSSO A, CHANDAR AK, MURAD MH, et al.Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome:A systematic review and network meta-analysis[J].Lancet Gastroenterol Hepatol, 2017, 2 (2) :94-102.

[30]European Association for the Study of Liver.EASL clinical practical guidelines:Management of alcoholic liver disease[J].J Hepatol, 2012, 57 (2) :399-420.

[31]GARCIA-SAENZ-de-SICILIA M, DUVOOR C, ALTAMIRANO J, et al.A day-4 lille model predicts response to corticosteroids and mortality in severe alcoholic hepatitis[J].Am J Gastroenterol, 2017, 112 (2) :306-315.

[32]GUSTOT T, MAILLART E, BOCCI M, et al.Invasive aspergillosis in patients with severe alcoholic hepatitis[J].J Hepatol, 2014, 60 (2) :267-274.

[33]CZAJA AJ.Diagnosis and management of autoimmune hepatitis[J].Clin Liver Dis, 2015, 19 (1) :57-79.

[34]ZHU B, YOU SL, WAN ZH, et al.Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure[J].World J Gastroenterol, 2014, 20 (23) :7473-7379.

[35]YEOMAN AD, WESTBROOK RH, ZEN Y, et al.Prognosis of acute severe autoimmune hepatitis (AS-AIH) :The role of eortieosteroids in modifying outcome[J].J Hepatol, 2014, 61 (4) :876-882.

[36]FISHER K, VUPPALANCHI R, SAXENA R.Drug-induced liver injury[J].Arch Pathol Lab Med, 2015, 139 (7) :876-887.

[37]CHEN M, SUZUKI A, BORLAK J, et al.Drug-induced liver injury:Interactions between drug properties and host factors[J].Hepatol, 2015, 63 (2) :503-514.

[38]KUMAGAI J, KANDA T, YASUI S, et al.Autoimmune hepatitis following drug-induced liver injury in an elderly patient[J].Clin J Gastroenterol, 2016, 9 (3) :156-159.

[39]HU PF, WANG PQ, CHEN H, et al.Beneficial effect of corticosteroids for patients with severe drug-induced liver injury[J].Dig Dis, 2016, 17 (9) :618-627.

[40]KARKHANIS J, VERNA EC, CHANG MS, et al.Steroid use in acute liver failure[J].Hepatology, 2014, 59 (2) :612-621.

[41]THURSE MR, RICHARDSON P, ALLISON M, et al.Prednisolone or pentoxifylline for alcoholic hepatitis[J].N Engl J Med, 2015, 372 (17) :1619-1628.

[42]LEE YS, KIM HJ, KIM JH, et al.Treatment of severe alcoholic hepatitis with corticosteroid, pentoxifylline, or dual therapy:A systematic review and meta-analysis[J].J Clin Gastroenterol, 2017, 51 (4) :364-377.

[43]YASUI S, FUJIWARA K, HAGA Y, et al.Infectious complications, steroid use and timing for emergency liver transplantation in acute liver failure:Analysis in a Japanese center[J].J Hepatobiliary Pancreat Sci, 2016, 23 (12) :756-762.

施引文献

资源附件(0)

访问统计